Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Net Cash Flow (2016 - 2025)

Fortress Biotech has reported Net Cash Flow over the past 13 years, most recently at -$6.8 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$6.8 million for Q4 2025, down 225.42% from a year ago — trailing twelve months through Dec 2025 was $21.8 million (up 188.74% YoY), and the annual figure for FY2025 was $21.8 million, up 188.74%.
  • Net Cash Flow for Q4 2025 was -$6.8 million at Fortress Biotech, down from $11.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for FBIO hit a ceiling of $56.5 million in Q1 2021 and a floor of -$65.7 million in Q2 2023.
  • Median Net Cash Flow over the past 5 years was -$14.7 million (2021), compared with a mean of -$7.7 million.
  • Biggest five-year swings in Net Cash Flow: surged 6279.89% in 2021 and later plummeted 225.42% in 2025.
  • Fortress Biotech's Net Cash Flow stood at $53.6 million in 2021, then tumbled by 155.26% to -$29.6 million in 2022, then skyrocketed by 129.1% to $8.6 million in 2023, then crashed by 124.37% to -$2.1 million in 2024, then plummeted by 225.42% to -$6.8 million in 2025.
  • The last three reported values for Net Cash Flow were -$6.8 million (Q4 2025), $11.8 million (Q3 2025), and -$17.0 million (Q2 2025) per Business Quant data.